

# Thomas Gremmel

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/2181433/thomas-gremmel-publications-by-year.pdf>

**Version:** 2024-04-24

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

105  
papers

1,699  
citations

24  
h-index

36  
g-index

112  
ext. papers

1,996  
ext. citations

5.1  
avg, IF

4.82  
L-index

#	Paper	IF	Citations
105	Peripheral versus central venous blood sampling does not influence the assessment of platelet activation in cirrhosis.. <i>Platelets</i> , <b>2022</b> , 1-8	3.6	0
104	Protease-activated receptor-mediated platelet aggregation in patients with type 2 diabetes on potent P2Y inhibitors.. <i>Diabetic Medicine</i> , <b>2022</b> , e14868	3.5	
103	Platelet-to-Lymphocyte Ratio as Marker of Platelet Activation in Patients on Potent P2Y Inhibitors.. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , <b>2022</b> , 27, 10742484221096524	2.6	2
102	Sex-specific platelet activation through protease-activated receptor-1 in patients undergoing cardiac catheterization. <i>Atherosclerosis</i> , <b>2021</b> , 339, 12-19	3.1	2
101	Microvascular rarefaction in patients with cerebrovascular events.. <i>Microvascular Research</i> , <b>2021</b> , 104300	3.7	1
100	Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in Acute Coronary Syndrome: Implications for Platelet Reactivity?. <i>Cardiovascular Drugs and Therapy</i> , <b>2021</b> , 35, 1183-1190	3.9	1
99	Activation of platelet-rich plasma by pulse electric fields: Voltage, pulse width and calcium concentration can be used to control and tune the release of growth factors, serotonin and hemoglobin. <i>PLoS ONE</i> , <b>2021</b> , 16, e0249209	3.7	2
98	Mean Corpuscular Volume Predicts Adverse Outcomes Following Peripheral Angioplasty With Stenting and Is Associated With On-Treatment Platelet Reactivity. <i>Angiology</i> , <b>2021</b> , 72, 16-23	2.1	0
97	Residual platelet reactivity in low-dose aspirin-treated patients with class 1 obesity. <i>Vascular Pharmacology</i> , <b>2021</b> , 136, 106819	5.9	1
96	Comparison of Light Transmission Aggregometry With Impedance Aggregometry in Patients on Potent P2Y12 Inhibitors. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , <b>2021</b> , 26, 260-268	2.6	0
95	Decreased Platelet Inhibition by Thienopyridines in Hyperuricemia. <i>Cardiovascular Drugs and Therapy</i> , <b>2021</b> , 35, 51-60	3.9	
94	Circulating MicroRNAs and Monocyte-Platelet Aggregate Formation in Acute Coronary Syndrome. <i>Thrombosis and Haemostasis</i> , <b>2021</b> , 121, 913-922	7	3
93	Glycocalyx as Possible Limiting Factor in COVID-19. <i>Frontiers in Immunology</i> , <b>2021</b> , 12, 607306	8.4	13
92	Platelet activation and aggregation in different centrifugal-flow left ventricular assist devices. <i>Platelets</i> , <b>2021</b> , 1-8	3.6	1
91	Platelet-to-lymphocyte and Neutrophil-to-lymphocyte Ratios Predict Target Vessel Restenosis after Infringuinal Angioplasty with Stent Implantation. <i>Journal of Clinical Medicine</i> , <b>2020</b> , 9,	5.1	10
90	Antithrombotic treatment strategies after PCI. <i>Lancet, The</i> , <b>2020</b> , 395, 865	40	
89	Ticagrelor Inhibits Toll-Like and Protease-Activated Receptor Mediated Platelet Activation in Acute Coronary Syndromes. <i>Cardiovascular Drugs and Therapy</i> , <b>2020</b> , 34, 53-63	3.9	13

88	Novel Antiplatelet Agents in Cardiovascular Disease. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , <b>2020</b> , 25, 191-200	2.6	11
87	Surrogate Markers of Neutrophil Extracellular Trap Formation are Associated with Ischemic Outcomes and Platelet Activation after Peripheral Angioplasty and Stenting. <i>Journal of Clinical Medicine</i> , <b>2020</b> , 9,	5.1	7
86	Sublingual microvasculature in diabetic patients. <i>Microvascular Research</i> , <b>2020</b> , 129, 103971	3.7	10
85	Association of Soluble Suppression of Tumorigenesis 2 (sST2) With Platelet Activation, Monocyte Tissue Factor and Ischemic Outcomes Following Angioplasty and Stenting. <i>Frontiers in Cardiovascular Medicine</i> , <b>2020</b> , 7, 605669	5.4	1
84	Oral Anticoagulation in patients with non-valvular atrial fibrillation and a CHA2DS2-VASc score of 1. <i>European Heart Journal</i> , <b>2019</b> , 40, 3010-3012	9.5	3
83	Oral anticoagulation in patients with non-valvular atrial fibrillation and a CHA2DS2-VASc score of 1: a current opinion of the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy and European Society of Cardiology Council on Stroke. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , <b>2019</b> , 5, 171-180	6.4	26
82	Bleeding and ischaemic outcomes in patients treated with dual or triple antithrombotic therapy: systematic review and meta-analysis. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , <b>2019</b> , 5, 226-236	6.4	20
81	Functional capillary impairment in patients with ventricular assist devices. <i>Scientific Reports</i> , <b>2019</b> , 9, 5909	4.9	8
80	Laboratory Monitoring of Antiplatelet Therapy <b>2019</b> , 653-682		
79	Using extracellular calcium concentration and electric pulse conditions to tune platelet-rich plasma growth factor release and clotting. <i>Medical Hypotheses</i> , <b>2019</b> , 125, 100-105	3.8	8
78	Protease-activated receptor-mediated platelet aggregation in acute coronary syndrome patients on potent P2Y inhibitors. <i>Research and Practice in Thrombosis and Haemostasis</i> , <b>2019</b> , 3, 383-390	5.1	11
77	Oral antiplatelet agents in cardiovascular disease. <i>Vasa - European Journal of Vascular Medicine</i> , <b>2019</b> , 48, 291-302	1.9	10
76	Acute Limb Ischemia after Intake of the Phenylethylamine Derivate NBOMe. <i>International Journal of Environmental Research and Public Health</i> , <b>2019</b> , 16,	4.6	3
75	Plasma Levels of snoRNAs are Associated with Platelet Activation in Patients with Peripheral Artery Disease. <i>International Journal of Molecular Sciences</i> , <b>2019</b> , 20,	6.3	3
74	β-Hydroxybutyrate dehydrogenase is associated with atherothrombotic events following infrainguinal angioplasty and stenting. <i>Scientific Reports</i> , <b>2019</b> , 9, 18200	4.9	5
73	Low Levels of High-Density Lipoprotein Cholesterol Are Linked to Impaired Clopidogrel-Mediated Platelet Inhibition. <i>Angiology</i> , <b>2018</b> , 69, 786-794	2.1	2
72	Bone cement in the right heart. <i>European Heart Journal Cardiovascular Imaging</i> , <b>2018</b> , 19, 825	4.1	
71	Circulating microRNAs identify patients at increased risk of in-stent restenosis after peripheral angioplasty with stent implantation. <i>Atherosclerosis</i> , <b>2018</b> , 269, 197-203	3.1	24

70	Non-vitamin K antagonist oral anticoagulants in patients with an increased risk of bleeding. <i>Wiener Klinische Wochenschrift</i> , <b>2018</b> , 130, 722-734	2.3	1
69	Research update for articles published in EJCI in 2016. <i>European Journal of Clinical Investigation</i> , <b>2018</b> , 48, e13016	4.6	
68	Response to aspirin therapy in patients with myeloproliferative neoplasms depends on the platelet count. <i>Translational Research</i> , <b>2018</b> , 200, 35-42	11	5
67	Sublingual functional capillary rarefaction in chronic heart failure. <i>European Journal of Clinical Investigation</i> , <b>2018</b> , 48, e12869	4.6	22
66	Decreased platelet inhibition by P2Y12 receptor blockers in anaemia. <i>European Journal of Clinical Investigation</i> , <b>2018</b> , 48, e12861	4.6	9
65	Tunable activation of therapeutic platelet-rich plasma by pulse electric field: Differential effects on clot formation, growth factor release, and platelet morphology. <i>PLoS ONE</i> , <b>2018</b> , 13, e0203557	3.7	8
64	Impaired glucose metabolism is associated with increased thrombin generation potential in patients undergoing angioplasty and stenting. <i>Cardiovascular Diabetology</i> , <b>2018</b> , 17, 131	8.7	6
63	Novel aspects of antiplatelet therapy in cardiovascular disease. <i>Research and Practice in Thrombosis and Haemostasis</i> , <b>2018</b> , 2, 439-449	5.1	28
62	Disaggregation Following Agonist-Induced Platelet Activation in Patients on Dual Antiplatelet Therapy. <i>Journal of Cardiovascular Translational Research</i> , <b>2017</b> , 10, 359-367	3.3	11
61	Oral antiplatelet therapy: impact for transfusion medicine. <i>Vox Sanguinis</i> , <b>2017</b> , 112, 511-517	3.1	10
60	Enzymatic lipid oxidation by eosinophils propagates coagulation, hemostasis, and thrombotic disease. <i>Journal of Experimental Medicine</i> , <b>2017</b> , 214, 2121-2138	16.6	58
59	Plasminogen activator inhibitor-1 4G/5G genotype and residual venous occlusion following acute unprovoked deep vein thrombosis of the lower limb: A prospective cohort study. <i>Thrombosis Research</i> , <b>2017</b> , 153, 71-75	8.2	1
58	The trapped mitral regurgitation. <i>European Heart Journal Cardiovascular Imaging</i> , <b>2017</b> , 18, 943	4.1	
57	Calpain-1 regulates platelet function in a humanized mouse model of sickle cell disease. <i>Thrombosis Research</i> , <b>2017</b> , 160, 58-65	8.2	4
56	Underlying mechanism and specific prevention of hemolysis-induced platelet activation. <i>Platelets</i> , <b>2017</b> , 28, 555-559	3.6	9
55	β-blockers are associated with decreased leucocyte-platelet aggregate formation and lower residual platelet reactivity to adenosine diphosphate after angioplasty and stenting. <i>European Journal of Clinical Investigation</i> , <b>2016</b> , 46, 1041-1047	4.6	6
54	Serum Cholinesterase Levels Are Associated With 2-Year Ischemic Outcomes After Angioplasty and Stenting for Peripheral Artery Disease. <i>Journal of Endovascular Therapy</i> , <b>2016</b> , 23, 738-43	2.5	7
53	Synergistic Inhibition of Both P2Y1 and P2Y12 Adenosine Diphosphate Receptors As Novel Approach to Rapidly Attenuate Platelet-Mediated Thrombosis. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , <b>2016</b> , 36, 501-9	9.4	35

52	New highly active antiplatelet agents with dual specificity for platelet P2Y1 and P2Y12 adenosine diphosphate receptors. <i>European Journal of Medicinal Chemistry</i> , <b>2016</b> , 107, 204-18	6.8	28
51	The Antiplatelet Effect of Clopidogrel Decreases With Patient Age. <i>Angiology</i> , <b>2016</b> , 67, 902-908	2.1	10
50	In Vivo and protease-activated receptor-1-mediated platelet activation in patients presenting for cardiac catheterization. <i>Platelets</i> , <b>2016</b> , 27, 308-16	3.6	5
49	Platelet Physiology. <i>Seminars in Thrombosis and Hemostasis</i> , <b>2016</b> , 42, 191-204	5.3	152
48	Liver Function is Associated With Response to Clopidogrel Therapy in Patients Undergoing Angioplasty and Stenting. <i>Angiology</i> , <b>2016</b> , 67, 835-9	2.1	2
47	Platelet-specific markers are associated with monocyte-platelet aggregate formation and thrombin generation potential in advanced atherosclerosis. <i>Thrombosis and Haemostasis</i> , <b>2016</b> , 115, 615-21	7	32
46	Research update for articles published in EJCI in 2014. <i>European Journal of Clinical Investigation</i> , <b>2016</b> , 46, 880-94	4.6	
45	Impact of variables of the P-selectin - P-selectin glycoprotein ligand-1 axis on leukocyte-platelet interactions in cardiovascular disease. <i>Thrombosis and Haemostasis</i> , <b>2015</b> , 113, 806-12	7	30
44	Calcium-Channel Blockers Attenuate the Antiplatelet Effect of Clopidogrel. <i>Cardiovascular Therapeutics</i> , <b>2015</b> , 33, 264-9	3.3	9
43	Research update for articles published in EJCI in 2013. <i>European Journal of Clinical Investigation</i> , <b>2015</b> , 45, 1005-16	4.6	0
42	Interleukin-6 and asymmetric dimethylarginine are associated with platelet activation after percutaneous angioplasty with stent implantation. <i>PLoS ONE</i> , <b>2015</b> , 10, e0122586	3.7	11
41	Comparison of Aggregometry with Flow Cytometry for the Assessment of Agonists-Induced Platelet Reactivity in Patients on Dual Antiplatelet Therapy. <i>PLoS ONE</i> , <b>2015</b> , 10, e0129666	3.7	32
40	Soluble CD40 Ligand in Aspirin-Treated Patients Undergoing Cardiac Catheterization. <i>PLoS ONE</i> , <b>2015</b> , 10, e0134599	3.7	9
39	Hypoxia Reoxygenation Treatment Induces Platelet Hyperactivity and Relieves Calpain-1-Mediated Inhibition of Platelet Aggregation in a Mouse Model of Severe Sickle Cell Disease. <i>Blood</i> , <b>2015</b> , 126, 413-413	4.7	13
38	Association of thrombin generation potential with platelet PAR-1 regulation and P-selectin expression in patients on dual antiplatelet therapy. <i>Journal of Cardiovascular Translational Research</i> , <b>2014</b> , 7, 126-32	3.3	5
37	Sex differences of leukocyte-platelet interactions and on-treatment platelet reactivity in patients with atherosclerosis. <i>Atherosclerosis</i> , <b>2014</b> , 237, 692-5	3.1	20
36	Microparticle-associated tissue factor activity in patients with acute unprovoked deep vein thrombosis and during the course of one year. <i>Thrombosis Research</i> , <b>2014</b> , 134, 1093-6	8.2	14
35	Human neutrophil defensins are associated with adenosine diphosphate-inducible neutrophil-platelet aggregate formation and response to clopidogrel in patients with atherosclerosis. <i>Translational Research</i> , <b>2014</b> , 164, 202-8	11	5

34	In vivo and protease-activated receptor-1-mediated platelet activation but not response to antiplatelet therapy predict two-year outcomes after peripheral angioplasty with stent implantation. <i>Thrombosis and Haemostasis</i> , <b>2014</b> , 111, 474-82	7	31
33	Residual thrombin generation potential is inversely linked to the occurrence of atherothrombotic events in patients with peripheral arterial disease. <i>European Journal of Clinical Investigation</i> , <b>2014</b> , 44, 319-24	4.6	15
32	Response to antiplatelet therapy and platelet reactivity to thrombin receptor activating peptide-6 in cardiovascular interventions: Differences between peripheral and coronary angioplasty. <i>Atherosclerosis</i> , <b>2014</b> , 232, 119-24	3.1	24
31	Obesity is associated with poor response to clopidogrel and an increased susceptibility to protease activated receptor-1 mediated platelet activation. <i>Translational Research</i> , <b>2013</b> , 161, 421-9	11	23
30	Preserved thrombin-inducible platelet activation in thienopyridine-treated patients. <i>European Journal of Clinical Investigation</i> , <b>2013</b> , 43, 689-97	4.6	15
29	Prasugrel reduces agonistsTinducible platelet activation and leukocyte-platelet interaction more efficiently than clopidogrel. <i>Cardiovascular Therapeutics</i> , <b>2013</b> , 31, e40-5	3.3	22
28	Residual platelet activation through protease-activated receptors (PAR)-1 and -4 in patients on P2Y12 inhibitors. <i>International Journal of Cardiology</i> , <b>2013</b> , 168, 403-6	3.2	25
27	Differential impact of cytochrome 2C9 allelic variants on clopidogrel-mediated platelet inhibition determined by five different platelet function tests. <i>International Journal of Cardiology</i> , <b>2013</b> , 166, 126-31 <sup>2</sup>	3.2	22
26	Response to antiplatelet therapy is independent of endogenous thrombin generation potential. <i>Thrombosis Research</i> , <b>2013</b> , 132, e24-30	8.2	7
25	Chronic kidney disease is associated with increased platelet activation and poor response to antiplatelet therapy. <i>Nephrology Dialysis Transplantation</i> , <b>2013</b> , 28, 2116-22	4.3	88
24	Hereditary amyloidosis caused by R554L fibrinogen A $\beta$ chain mutation in a Spanish family and review of the literature. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , <b>2013</b> , 20, 72-9	2.7	17
23	Differential impact of inflammation on six laboratory assays measuring residual arachidonic acid-inducible platelet reactivity during dual antiplatelet therapy. <i>Journal of Atherosclerosis and Thrombosis</i> , <b>2013</b> , 20, 630-45	4	15
22	Impact of diabetes on platelet activation in different manifestations of atherosclerosis. <i>Swiss Medical Weekly</i> , <b>2013</b> , 143, w13800	3.1	6
21	Influence of cytochrome 2C19 allelic variants on on-treatment platelet reactivity evaluated by five different platelet function tests. <i>Thrombosis Research</i> , <b>2012</b> , 129, 616-22	8.2	19
20	High levels of platelet-monocyte aggregates after valve replacement for aortic stenosis: relation to soluble P-selectin and P-selectin glycoprotein ligand-1 genes. <i>Thrombosis Research</i> , <b>2012</b> , 129, 453-8	8.2	9
19	A high maintenance dose increases the inhibitory response to clopidogrel in patients with high on-treatment residual platelet reactivity. <i>International Journal of Cardiology</i> , <b>2012</b> , 160, 109-13	3.2	13
18	The Thr715Pro variant impairs terminal glycosylation of P-selectin. <i>Thrombosis and Haemostasis</i> , <b>2012</b> , 108, 963-72	7	8
17	Frequency of heparin/platelet factor 4-dependent platelet antibodies in patients undergoing angioplasty and stenting for cardiovascular disease and their role for on-clopidogrel platelet reactivity. <i>Clinical Research in Cardiology</i> , <b>2012</b> , 101, 445-52	6.1	2

16	Soluble p-selectin, D-dimer, and high-sensitivity C-reactive protein after acute deep vein thrombosis of the lower limb. <i>Journal of Vascular Surgery</i> , <b>2011</b> , 54, 48S-55S	3.5	38
15	The influencing factors for clopidogrel-mediated platelet inhibition are assay-dependent. <i>Thrombosis Research</i> , <b>2011</b> , 128, 352-7	8.2	39
14	The P-selectin gene Pro715 allele and low levels of soluble P-selectin are associated with reduced P2Y12 adenosine diphosphate receptor reactivity in clopidogrel-treated patients. <i>Atherosclerosis</i> , <b>2011</b> , 217, 135-8	3.1	5
13	Clinical, genetic and confounding factors determine the dynamics of the in vitro response/non response to clopidogrel. <i>Thrombosis and Haemostasis</i> , <b>2011</b> , 106, 211-8	7	30
12	Recurrent circumflex artery embolization due to a free-floating fibroelastoma at the aortic valve. <i>Annals of Thoracic Surgery</i> , <b>2011</b> , 91, 1626	2.7	
11	Comparison of methods to evaluate aspirin-mediated platelet inhibition after percutaneous intervention with stent implantation. <i>Platelets</i> , <b>2011</b> , 22, 188-95	3.6	28
10	Platelet-monocyte cross talk and tissue factor expression in stable angina vs. unstable angina/non ST-elevation myocardial infarction. <i>Platelets</i> , <b>2011</b> , 22, 530-6	3.6	14
9	Is TRAP-6 suitable as a positive control for platelet reactivity when assessing response to clopidogrel?. <i>Platelets</i> , <b>2010</b> , 21, 515-21	3.6	26
8	The influence of proton pump inhibitors on the antiplatelet potency of clopidogrel evaluated by 5 different platelet function tests. <i>Journal of Cardiovascular Pharmacology</i> , <b>2010</b> , 56, 532-9	3.1	28
7	Calcium-channel blockers decrease clopidogrel-mediated platelet inhibition. <i>Heart</i> , <b>2010</b> , 96, 186-9	5.1	84
6	Gross proteinuria and subacute renal failure after coronary angiography - a case report of cholesterol crystal embolization. <i>Wiener Klinische Wochenschrift</i> , <b>2010</b> , 122, 251-4	2.3	2
5	Adenosine diphosphate-inducible platelet reactivity shows a pronounced age dependency in the initial phase of antiplatelet therapy with clopidogrel. <i>Journal of Thrombosis and Haemostasis</i> , <b>2010</b> , 8, 37-42	15.4	55
4	Comparison of methods to evaluate clopidogrel-mediated platelet inhibition after percutaneous intervention with stent implantation. <i>Thrombosis and Haemostasis</i> , <b>2009</b> , 101, 333-339	7	102
3	Smoking promotes clopidogrel-mediated platelet inhibition in patients receiving dual antiplatelet therapy. <i>Thrombosis Research</i> , <b>2009</b> , 124, 588-91	8.2	50
2	The formation of monocyte-platelet aggregates is independent of on-treatment residual agonists-inducible platelet reactivity. <i>Atherosclerosis</i> , <b>2009</b> , 207, 608-13	3.1	25
1	Comparison of methods to evaluate clopidogrel-mediated platelet inhibition after percutaneous intervention with stent implantation. <i>Thrombosis and Haemostasis</i> , <b>2009</b> , 101, 333-9	7	23